KALV Competitors & Alternatives
Compare Kalvista Pharmaceuticals Inc with similar stocks in the same industry
Biotechnology
KALV
Main Stock$26.79
Tradestie Score
59
Market Cap
$608.81M
Revenue Growth
0.3%
Analyst Upside
+6.8%
Top Competitors
221 stocks in Biotechnology| Company | Price | Market Cap | P/E | Score | Action |
|---|---|---|---|---|---|
|
PHVS
Pharvaris N.V. Ordinary Shares
|
$29.68
|
$1.55B | - | 59 | Compare |
|
NVAX
Novavax Inc
|
$9.21
|
$1.54B | - | 60 | Compare |
|
AUPH
Aurinia Pharmaceuticals Inc
|
$15.22
|
$1.50B | 7.1 | 61 | Compare |
|
GPCR
Structure Therapeutics Inc. American Depositary Shares
|
$39.19
|
$1.50B | - | 58 | Compare |
|
AMLX
Amylyx Pharmaceuticals, Inc. Common Stock
|
$13.58
|
$1.49B | - | 52 | Compare |
|
RCUS
Arcus Biosciences, Inc.
|
$23.43
|
$1.43B | - | 54 | Compare |
|
JANX
Janux Therapeutics, Inc. Common Stock
|
$14.52
|
$1.42B | - | 57 | Compare |
|
SNDX
Syndax Pharmaceuticals, Inc.
|
$19.94
|
$1.35B | - | 54 | Compare |
|
MPLT
MPLT
|
$28.75
|
$1.33B | - | 57 | Compare |
|
RAPP
Rapport Therapeutics, Inc. Common Stock
|
$37.72
|
$1.32B | - | 56 | Compare |
More KALV Analysis
Data updated: May 25, 2026 | Industry: Biotechnology (SIC 2834)
221 stocks in this industry